顺铂联合白细胞介素-2治疗恶性胸腔积液32例  

Treatment of Malignant Pleural Effusion Using Cisplatin and IL-2 into Pleural Cavity

作　　者：张荣生[1] 

机构地区：[1]大理学院附属医院内科,云南大理671000

出　　处：《大理学院学报（综合版）》2006年第4期16-17,共2页Journal of Dali University

摘　　要：目的:探讨胸腔注入顺铂(DDP)联合白细胞介素一2(IL-2)治疗恶性胸腔积液疗效。方法:58例患者均病理确诊为恶性胸腔积液,随机分为二组,治疗组(32例)在胸腔内注入DDP,白细胞介素-2,对照组(26例)在胸腔内注入DDP,两组均在1周及2周后各重复注药1次,共3次,观察疗效,毒副反应及生活质量。结果:治疗组总有效率为84.4%,对照组57.7%,差异有显著性(P<0.015)。治疗组Kamofsky评分>70分者较对照组有显著提高(P<0.05),两组在毒性反应上无显著性差异(P>0.05)。结论:顺铂白介素-2胸腔灌注能有效控制恶性胸腔积液,毒副作用少,联合疗效肯定。Objective： To study the therapeutic efficacy of intrapersonal injection of cisplatin（DDP） and interleukin-2 （IL-2） in malignant pleural effusions. Methods： Fifty-eight patients with malignant pleural effusion were divided randomly into 2 groups, cisplatin（DDP） and IL-2 were injected into pleural Cavity in therapy Group （T）, and only DDP was given in control group（C ）. Then the efficacy toxicity and quality of life were evaluated. Results： The response rate was 84.4% in T group and 57.7% in C group. The difference was significant （P〈0.05）. The Kamofsky score was higher in T group than that of the control group（P〈0.05 ）. Adverse effects were no significant difference in two groups（ P〉0.05 ）. Conclusions： The results suggest that intrapleural injection of DDP and IL-2 may be safe and effective in treating malignant pleural effusion.

关 键 词：顺铂 白细胞介素-2 恶性胸腔积液 药物疗法 

分 类 号：R969.4[医药卫生—药理学]